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Background: Voltage-gated sodium channels Nav1.8 and Nav1.9 are expressed preferentially in small diameter
sensory neurons, and are thought to play a role in the generation of ectopic activity in neuronal cell bodies and/or
their axons following peripheral nerve injury. The expression of Nav1.8 and Nav1.9 has been quantified in human
lingual nerves that have been previously injured inadvertently during lower third molar removal, and any
correlation between the expression of these ion channels and the presence or absence of dysaesthesia
investigated.
Results: Immunohistochemical processing and quantitative image analysis revealed that Nav1.8 and Nav1.9 were
expressed in human lingual nerve neuromas from patients with or without symptoms of dysaesthesia. The level of
Nav1.8 expression was significantly higher in patients reporting pain compared with no pain, and a significant
positive correlation was observed between levels of Nav1.8 expression and VAS scores for the symptom of tingling.
No significant differences were recorded in the level of expression of Nav1.9 between patients with or without pain.
Conclusions: These results demonstrate that Nav1.8 and Nav1.9 are present in human lingual nerve neuromas, with
significant correlations between the level of expression of Nav1.8 and symptoms of pain. These data provide further
evidence that changes in expression of Nav1.8 are important in the development and/or maintenance of nerve
injury-induced pain, and suggest that Nav1.8 may be a potential therapeutic target.
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The mechanisms underlying the development of chronic
pain following peripheral nerve injury are still poorly
understood, and neuropathic pain remains a substantial
clinical problem. Injury to a peripheral nerve often leads
to the development of a neuroma, a disordered mass of
axons embedded within the connective and scar tissue
of a damaged nerve trunk, and this site has been shown
to generate abnormal and spontaneous discharge [1-3].
Within sensory neurons, voltage-gated sodium channels
(VGSCs) are responsible for the initiation and gener-
ation of action potentials. There is a growing body of* Correspondence: e.v.bird@sheffield.ac.uk
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reproduction in any medium, provided the orevidence that changes in the transcriptional regulation
of VGSCs plays a pivotal role in the generation and
maintenance of ectopic activity from injured or spared
axons at the site of a nerve injury, with a number of sub-
types being of particular significance [4-8]. Of the nine
distinct voltage-gated sodium channel subtypes identified
in mammals, the physiological properties and patterns of
expression within the nervous system, of subtypes Nav1.7,
1.8 and 1.9, suggests they may play important role(s) in
the initiation and/or maintenance of chronic pain [9-11].
Evidence indicates that Nav1.7, 1.8 and 1.9 are preferen-
tially expressed in nociceptive fibres of the peripheral
nervous system, and they have been shown by a number
of studies to be predominantly localised in the pain-
conducting small and medium-sized neurons of the dorsal
root and trigeminal ganglia [12-17]. However there is also. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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DRG neurons including myelinated A fibres [18]. A num-
ber of studies have indicated a role for Nav1.7 in chronic
pain in humans [11,19-21]; however, a recent immunohis-
tochemical study in our laboratory reported that although
the sodium channel subtype Nav1.7 was expressed in hu-
man lingual nerve neuromas, there was no direct relation-
ship between the level of expression and the patients’
symptoms of dysaesthesia [22]. Therefore further investi-
gation into the role that sodium channel subtypes Nav1.8
and 1.9 play in the propagation and initiation of chronic
painful symptoms such as dysaesthesia will further our
understanding of the underlying mechanisms and may
identify useful targets for novel analgesics.
Peripheral nerves in the orofacial region are suscep-
tible to injury during routine oral surgical procedures.
The lingual nerve, a sensory branch of the mandibular
division of the trigeminal nerve, is susceptible to injury
during routine oral surgical procedures or as a conse-
quence of facial trauma. Its anatomical position makes it
vulnerable to damage during the surgical extraction of
lower third molar teeth, and patients who sustain such
an injury are often left with a loss of sensation to the ip-
silateral side of their tongue. Furthermore a significant
proportion of these patients go on to develop abnormal
and unpleasant persistent sensory disturbances such as
dysaesthesia, which can be either spontaneous or in-
duced by movement or touching of the tongue [23,24].
There are currently no satisfactory methods for the
treatment of dysaesthesia and patients who have sus-
tained a lingual nerve injury, and show little or no
spontaneous recovery, are referred for microsurgical
repair of the damaged nerve. This has resulted in the
collection of an extensive archive of lingual nerve
neuromas [25].
With the aim of investigating the role that sodium
channel subtypes play in chronic pain arising as a result
of lingual nerve injury, the expression of Nav1.8 and
Nav1.9 within nerve tissue (as identified by the general
neuronal marker PGP9.5) was examined and quantified
in human lingual nerve neuromas, and any association
between the expression of these sodium channels and
the presence or absence of symptoms of dysaesthesia
identified. Data from this study show that Nav1.8 and
Nav1.9 are expressed in human lingual nerve neuromas,
with a significant increase in levels of Nav1.8 expression
seen in neuromas taken from patients with symptoms of
dysaesthesia. Furthermore a positive correlation of the
expression of Nav1.8 with the symptom and degree of
tingling experienced by the patients was recorded.
Results
Of the thirteen specimens selected for analysis, nine were
taken from female patients, and four from male patients,with the mean age (±SEM) at the time of microsurgical re-
pair of their lingual nerves being 31.2 ± 1.76 years (range
22–46 years). No labelling was present in tissue sections
where primary antibodies for PGP9.5 and the sodium
channel subtypes were omitted, as previously described
for PGP9.5 [22] and as shown in Figure 1.
Qualitative and quantitative expression of Nav1.8 in
PGP9.5-labelled lingual neuroma tissue
Immunoreactivity to the general neuronal marker
PGP9.5, and Nav1.8 was present in all of the neuromas
analysed; however, the level and pattern of expression
varied between the individual specimens (Table 1). Some
neuromas expressed high levels of Nav1.8 immunolabel-
ling that was bright and appeared to be axonal-specific,
showing positive co-localisation with PGP9.5. In con-
trast, other neuromas exhibited a very low level of
Nav1.8 immunoreactivity. However, overall, the level of
Nav1.8 expression appeared to be higher in neuroma
specimens from patients with symptoms of dysaesthesia
compared with that in specimens from patients with no
symptoms (Figure 2).
Quantitative analysis of the neuromas labelled for
PGP9.5 and Nav1.8 revealed that the fraction of PGP9.5
labelled tissue expressing Nav1.8 ranged from 0.21% to
54.83% (Table 1). In neuromas taken from patients ex-
periencing no symptoms of dysaesthesia, Nav1.8 levels
ranged from 0.21% to 33.06%, and in neuromas from pa-
tients who did experience painful dysaesthesia, fractional
expression of Nav1.8 ranged from 20.19% to 54.83%.
Further statistical analysis confirmed the above qualitative
observation and demonstrated that there was a statistical
significant difference in Nav1.8 expression between the
patients reporting symptoms of dysaesthesia compared
with those reporting no symptoms (unpaired t-test p =
0.0087; pain, 31.82 ± 4.54 [SEM]%, no pain 10.52 ± 4.93
[SEM]%) (Figure 2).
The thirteen neuromas were initially selected from the
archive based on the highest and lowest VAS scores for
symptoms of dysaesthesia, with no bias given to gender,
age or length of time between the initial injury and the
subsequent surgical nerve repair. Four of the thirteen
specimens were from male patients, and nine were from
female patients. Statistical analysis of the pooled male
and female data revealed that there was no significant
difference between the level of expression of Nav1.8 in
male (mean 24.53%) and female (mean 20.86%, p = 0.72)
specimens, and the same was true for the symptomatic fe-
males (31.55%) versus symptomatic males (mean 32.18%,
p = 0.95). Within the pooled data taken from the female
specimens, there was no difference between the levels of
Nav1.8 expressed in non-painful neuromas (unpaired t-
test p = 0.08; mean 12.31 ± 5.62 [SEM]%) and painful
neuromas (mean 31.55 ± 8.04 [SEM]%). Correlation co-
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Figure 1 Nav1.8 and Nav1.9 expression in lingual neuromas. A and B. Nav1.8 and Nav1.9 immunolabelling was bright and appeared to be
axon-specific, showing positive co-localisation with PGP9.5. Images showing immunofluorescent labelling in the lingual nerve neuromas for
PGP9.5 (green) and Nav1.8 and Nav1.9 (red). The composite images show the expression of Nav1.8 and Nav1.9 within PGP9.5 labelled tissue
(yellow). C. No positive staining for sodium channel subtypes was present where the primary antibodies were omitted. Images of lingual nerve
neuromas following incubation with Nav1.8 antibody, Nav1.9 antibody, and secondary antibody alone (Control). Scale bar = 100 μm (A and C);
50 μm (B).
Table 1 Details of the patients included in the study, including VAS scores, gender, age of the patients, time between
the initial injury and surgical repair, and the Nav1.8 and Nav1.9 expression levels
No symptoms of dysaesthesia
Neuroma specimen % Nav1.8 % Nav1.9 Gender
(male/female)
Age (years) Pain VAS Tingling VAS Discomfort VAS Time between injury
and repair (months)
1 10.62 6.86 F 31 0 0 44 18
2 33.06 5.42 F 25 1 2 10 21
3 12.54 11.87 F 28 1 0 81 16
4 0.21 8.25 F 39 1 2 39 26
5 5.11 - F 31 1 1 48 11
6 1.58 13.39 M 28 3 1 7 6
Symptoms of dysaesthesia
Neuroma specimen % Nav1.8 % Nav1.9 Gender
(male/female)
Age (years) Pain VAS Tingling VAS Discomfort VAS Time between injury
and repair (months)
7 38.55 9.64 M 28 65 81 50 41
8 54.83 16.33 F 36 29 97 70 14
9 20.19 18.97 F 22 34 99 42 15
10 32.68 14.15 M 27 66 8 50 7
11 29.77 1.12 F 34 79 95 95 9
12 21.42 10.72 F 31 81 50 99 53
13 25.32 18.67 M 46 78 77 75 288
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Figure 2 Nav1.8 is expressed in human lingual nerve neuromas. A. Nav1.8 immunolabelling appeared greater in lingual nerve neuromas
from patients with symptoms of dysaesthesia. Images of lingual nerve neuromas from patients without or with symptoms of dysaesthesia, showing
double labelling with the general neuronal marker PGP9.5 (green) and Nav1.8 (red). Scale bar, 100 μm. B. The mean percentage area (± SEM) of PGP9.5
labelled tissue containing Nav1.8 was significantly higher in lingual nerve neuroma specimens taken from patients with symptoms of pain (unpaired
t-test p = 0.0087; no pain 10.52 ± 4.93%, pain 31.82 ± 4.54%).
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no association between the level of Nav1.8 expression
and either the age of the patient or the time between
the initial nerve injury and the subsequent surgical
nerve repair. However, whilst there was no relation-
ship between the expression of Nav1.8 and the pain
or discomfort VAS scores, the level of Nav1.8 expres-
sion correlated significantly with the presence of dysaes-
thesia and reported levels of tingling (Pearson’s Correlation
r = 0.64, p = 0.02) (Figure 3).Qualitative and quantitative expression of Nav1.9 in
PGP9.5-labelled lingual neuroma tissue
Neuromas processed for PGP9.5 and Nav1.9 showed im-
munoreactivity to PGP9.5 in all specimens, whilst only
twelve of the thirteen specimens showed positive immu-
noreactivity to Nav1.9. The PGP9.5 labelling was bright
and uniform throughout the sections, showing good
nerve fibre specificity (Figure 4). The PGP9.5 labelling
highlighted the extent of nerve injury and axon disrup-
tion, and in many of the specimens the site of the initial
Figure 3 Correlation of Nav1.8 and Nav1.9 with symptoms of pain, tingling and discomfort. A. Regression plots showing the relationship
between the expression of Nav1.8 and VAS scores for pain, tingling and discomfort as reported by the patient. The level of Nav1.8 expression
correlated positively with reported levels of tingling (Pearson’s Correlation r = 0.64, p = 0.02). B. Regression plots showing the relationship
between the expression of Nav1.9 and VAS scores for pain, tingling and discomfort as reported by the patient, revealed there was no significant
correlation between the degree of symptoms experienced and the level of Nav1.9 expression.
Bird et al. Molecular Pain 2013, 9:52 Page 5 of 11
http://www.molecularpain.com/content/9/1/52injury was clear. In the twelve neuromas that were posi-
tively stained for Nav1.9, immunoreactivity was bright and
of a pin-prick appearance, showing co-expression with
PGP9.5 labelled tissue. However, the level of expression
appeared to vary with a qualitative assessment suggesting
that Nav1.9 expression was higher in neuromas from pa-
tients with symptoms of dysaesthesia (Figure 4). One of
the neuroma specimens (specimen 5) showed no Nav1.9
staining, and the appearance of the sections suggested that
the Nav1.9 primary antibody may have failed to bind to
the tissue, and for this reason was excluded from the
quantitative analysis.
The percentage area of PGP9.5 that contained Nav1.9
immunoreactivity varied greatly between the specimenssampled (Table 1), ranging from 5.42-13.39% (mean
9.16 ± 1.51 [SEM]%) in neuromas from patients with no
symptoms of dysaesthesia, and 1.12-18.97% (mean 12.8 ±
2.38 [SEM]%) in neuromas from patients with symptoms
of dysaesthesia. Statistical analysis revealed that there
was no significant difference between these two groups
(unpaired t-test p = 0.27) (Figure 4). Of the twelve speci-
mens expressing Nav1.9, four were from male patients,
and eight were from female patients, with no significant
difference between Nav1.9 levels in the pooled data from
males (mean 9.94%) and females (mean 13.96%, p = 0.24).
Furthermore, analysis showed that there was no dif-
ference in levels of Nav1.9 expression between the non-
symptomatic female specimens (mean 8.10%) and the
AB
Figure 4 Nav1.9 is expressed in human lingual nerve neuromas. A. Nav1.9 immunolabelling appeared greater in lingual nerve neuromas
from patients with symptoms of dysaesthesia. Images of lingual nerve neuromas from patients without or with symptoms of dysaesthesia,
showing double labelling with the general neuronal marker PGP9.5 (green) and Nav1.9 (red). Scale bar, 100 μm. B. The mean percentage area (±
SEM) of PGP9.5 labelled tissue containing Nav1.9 did not reveal any significant differences between the two groups of neuromas (unpaired t-test
p = 0.27; no pain 9.16 ± 1.51%, pain 12.8 ± 2.38%).
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The mean age of the patients with no symptoms of dys-
aesthesia was 30.33 (± 1.96) years compared with 32
(± 2.92) years for patients with symptoms of dysaes-
thesia, and correlation co-efficient analysis revealed
there was no significant correlation between the level
of Nav1.9 expression and the age of the patient. Further
correlation coefficient analysis of the data revealed that in
both the non-symptomatic and symptomatic groups of
neuroma specimens, there was no significant relationshipbetween the level of Nav1.9 expression and the VAS scores
for pain, tingling or discomfort, or the time between the
initial nerve injury and repair (Figure 3).
Discussion
Data from this study show that Nav1.8 and Nav1.9
are present in human lingual nerve neuromas, and
provide the first quantitative demonstration that expres-
sion of Nav1.8 is significantly higher in painful lingual
nerve neuromas compared with non-painful neuromas.
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level of Nav1.8 expression and the degree of tingling expe-
rienced by the patients was revealed, suggesting that this
sodium channel subtype may have an important role in
the development and/or maintenance of neuropathic pain
and the symptoms of tingling arising in the lingual nerve
after a peripheral injury. However, our data indicate that
elevated levels of Nav1.9 may not play a significant role in
the generation and maintenance of lingual nerve injury in-
duced neuropathic pain.
Previous studies in our laboratory have investigated the
expression of a number of known mediators of neuro-
pathic pain including Nav1.7, P2X3, P2X7, TRPV1, and
TRPA1 [22,26-29], and described their presence in human
lingual nerve neuroma specimens. Quantitative immuno-
histochemical protocols revealed that there was no signifi-
cant difference in expression of any of these mediators,
including the sodium channel subtype Nav1.7, in lingual
nerve neuromas associated with or without symptoms of
dysaesthesia. Furthermore there was no correlation with
patient VAS scores for pain, tingling or discomfort, thus
suggesting that despite these previously described media-
tors of neuropathic pain being expressed at the site of
injury, elevated levels of expression of these molecules
does not appear to play a primary role in the development
or maintenance of neuropathic pain arising as a result of
lingual nerve injury.
A number of studies have examined the expression of
multiple sodium channel subtypes in injured human
nerve specimens over the past twenty years. England
and colleagues [30] were the first to report an accumula-
tion of sodium channels within the tips of human injured
axons, that was significantly higher in painful neuromas
compared to control nerves [31]. The idea that such an
increased accumulation may play a role in the generation
of ectopic axonal excitability has propelled attempts to
determine the exact role sodium channels play in the
underlying mechanisms of pain, with the aim of develop-
ing target specific, low side effect therapeutic treatments.
A study conducted by Coward and colleagues [32] used
antibodies specific for the individual sodium channel sub-
types, and reported a marked increase in the expression of
Nav1.8, but not Nav1.9, immunoreactive fibres, in distal
limb neuromas from patients experiencing chronic hyper-
algesia and allodynia. The authors postulated that the in-
crease in expression of Nav1.8 at the site of nerve injury
was due to a translocation of Nav1.8 from the site of pro-
duction within the DRG, as confirmed by a decrease in
Nav1.8-immunoreactive cell bodies. Black et al. [11] re-
ported an upregulation of Nav1.8 immunofluorescence,
accompanied by an accumulation of activated p38 and
ERK1/2, in painful neuroma tissue when compared with
control nerve – a portion of nerve tissue excised proximal
to the neuroma and thus acting as its own control. Inkeeping with our results, and those of Coward and col-
leagues [32], Black et al. [11] did not see an increase in ex-
pression of Nav1.9 immunofluorescence in painful human
nerve neuromas. Differences between these studies and
the current study relate to the comparison of Nav1.8 and
Nav1.9 levels in injured nerve and control nerve. However,
the present study has compared differences between in-
jured symptomatic vs. non-symptomatic neuromas, and
this enables the study of differences specifically re-
lated to the presence of pain – as opposed to differ-
ences related to the presence of injury. An increase in
Nav1.8 immunoreactivity in painful neuromas com-
pared to non-painful neuromas and control nerves
was described by Kretschmer et al. [33], however this
was a qualitative study, reporting a pronounced im-
pression, rather than a quantified level. In the present
study, we were unable to examine the expression of
Nav1.8 and Nav1.9 in human control lingual nerve
and trigeminal ganglion tissue, and thus we were un-
able to determine how sodium channel subtype ex-
pression in the lingual nerve neuromas compares to
that seen in normal nerves, and whether it correlates
with changes in expression in the trigeminal ganglion.
However, other studies have shown very low levels of
staining for sodium channels in normal peripheral
nerves [33,34].
Voltage-gated sodium channels play a key role in the
initiation and propagation of action potentials, and it is
now widely accepted that changes in sodium channel ex-
pression and their accumulation at sites of peripheral
nerve injury may contribute to the mechanisms under-
lying the hyperexcitability that develops in sensory neu-
rones following peripheral nerve axotomy. Expressed
preferentially in small diameter sensory neurons in the
periphery [4], TTX-r sodium channel subtypes Nav1.8
and 1.9 have electrophysiological characteristics that
enable them to remain persistently active [35], and re-
cover from inactivation rapidly [36], thus contributing to
hyperexcitability of primary afferents that can bombard
the CNS with a stream of action potentials. Studies
employing transgenic knockout mice models reported
the suppression of both spontaneous activity recorded
from the site of nerve injury, and the ability to sense
cold pain or mechanical pressure in a Nav1.8 null mouse
[37]. Furthermore, Nav1.8 null mice showed reduced
pain behaviour and no hyperalgesic response to capsa-
icin, when compared with their wild type littermates
[38]. However these findings are not universal and other
studies using Nav1.8 null mice have demonstrated that
Nav1.8 is not essential for neuropathic pain behaviour
[39]. Lai et al. [40] reported that injection of antisense
RNA to Nav1.8 removed all sensitisation to mechanical
and thermal stimuli in animals that had undergone a
spinal nerve injury, which returned following the removal
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transcripts and proteins of Nav1.8 and 1.9 were signifi-
cantly reduced in the DRG tissue, which was accompanied
by a significant attenuation of the currents produced by
these channels [41,42]. Consistent with our study and the
expression of Nav1.8 and Nav1.9 in human trigeminal
nerve tissue, Davies et al. [34] reported an accumulation
of Nav1.8 and 1.9 at the site of inferior alveolar nerve tran-
section in the ferret, with a down-regulation of Nav1.8
mRNA in small sized trigeminal ganglion cells following
inferior alveolar nerve injury in the rat [43].
Transgenic mouse models and loss of function studies
suggest that different voltage-gated sodium channel
subtypes are associated with different types of pain (for re-
view see [5]). Responsible for the persistent TTX-r current
in small diameter sensory neurons [44], strong evidence
now exists that Nav1.9 plays a major role in mediating
inflammatory rather than neuropathic pain, and this may
explain our data and the absence of a significant difference
in the levels of Nav1.9 expression in lingual nerve neur-
omas with and without symptoms of pain. A knock-out
mouse study by Maingret and colleagues [45] reported the
failure of inflammatory mediators bradykinin, ATP, hista-
mine, prostaglandin-E2 and norepinephrine, to sensitise
sensory neurons in Nav1.9 null mice. In contrast, wild
type mice were able to upregulate Nav1.9 channel activity
when an inflammatory soup was applied, thus suggesting
that Nav1.9 is a crucial player in inflammation, contribut-
ing to nociceptive hyperexcitability. Studies examining the
expression of Nav1.8 and Nav1.9 in other chronic inflam-
matory pain models have reported an increased expres-
sion in painful inflamed human dental pulp tissue, when
compared with normal non-painful pulps [46-48], and in a
Freund’s complete adjuvant (FCA) model of chronic in-
flammatory joint pain, Nav1.8 and Nav1.9 expression in
associated DRG cells was upregulated, up to 28 days post-
FCA insult [49].
It might have been expected that the length of time
between the initial injury and the subsequent repair sur-
gery would affect the level of expression of Nav1.8 or
Nav1.9, or the VAS scores associated with the symptoms
experienced by the patients; however, this was not the
case. A time course study of sodium channel subtype ex-
pression in animal models of neuropathic pain reported
that after initial alterations in sodium channel expression
and accumulation, changes revert to normal relatively
quickly [43]. However in the case of the human nerve
study, neuroma specimens were obtained after a rela-
tively long period of time after the initial injury and so
the early changes seen in the animal studies may not
have been detected. Indeed it might have been expected
that sodium channel expression would have reduced to
normal levels in our specimens, but this did not appear
to be the case with marked variation across the wholeset of specimens, and the lack of any normal control tis-
sue makes interpretation of this variation difficult.
Conclusions
In summary, our data have shown that Nav1.8 and
Nav1.9 are expressed in human lingual nerve neuromas.
Despite the level of expression showing wide variation
between the specimens sampled, results from this study
provide the first demonstration of a statistically signifi-
cant difference in the levels of Nav1.8 in lingual nerve
neuromas from patients experiencing painful symptoms
of dysaesthesia, compared with those from patients ex-
periencing no symptoms of dysaesthesia. Furthermore,
the level of expression of Nav1.8 correlated significantly
and positively with reported levels of tingling (VAS) as
reported by the patient. Elevated expression of Nav1.8
appears to be important in the development and/or
maintenance of injury-induced neuropathic pain in the
lingual nerve.
Methods
Neuroma specimens
Ethical approval for the study was obtained from the
South Sheffield Research Ethics Committee, and all the
specimens were collected with the patients’ informed con-
sent. All patient details were kept confidential and each
specimen was given a unique code to be used throughout
the study. Specimens were obtained from our archive of
84 lingual nerve neuromas collected from patients re-
ferred to the Charles Clifford Dental Hospital Oral and
Maxillofacial Medicine and Surgery Department, from
throughout the United Kingdom, between 2000 and 2008.
The light and microscopic characteristics of these neur-
omas has been described previously [50]. For a detailed
description of the surgical removal and repair of the lin-
gual nerve, see [51]. Clinical histories and symptoms were
obtained pre-operatively using a questionnaire, and pa-
tients asked whether the affected part of the tongue was
painful, and whether they had any tingling either spontan-
eously or caused by moving or touching their tongue. Fur-
thermore, patients scored the extent of their pain, tingling
and discomfort using visual analogue scales (VAS). These
tests revealed that patients suffered either anaesthesia or a
significant degree of hypoaesthesia, in addition to variable
degrees of dysaesthesia, on the side of the tongue inner-
vated by the damaged nerve, thus confirming the need
for further exploration and surgical repair of the nerve.
Thirteen ‘neuroma-in-continuity’ specimens were selected
from the archive. These neuromas all had some element
of nerve tissue bridging the gap between the central and
distal stumps of the damaged nerve. Seven specimens
were categorized as from patients with the most severe
symptoms, where patients experienced either pain or
unpleasant tingling either spontaneously or initiated
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mens were categorized as from patients with no symp-
toms of dysaesthesia, as there was a complete absence of
pain or unpleasant tingling reported at the time of clinical
examination and pain questionnaire.
Tissue processing
Immediately following surgical removal of the neuroma,
the central end was marked with a 9/0 Ethilon (Ethicon,
Edinburgh, UK) suture and the specimen placed in 2%
Zamboni’s fixative (0.1 mol/L phosphate buffer, pH 7.4,
containing 4% paraformaldehyde and 0.2% picric acid) for
24 hours at 4°C. Following fixation, the specimen was
cryoprotected in 30% sucrose solution for 12 hours at 4°C,
and embedded longitudinally in Tissue-Tek® O.C.T.
compound (Sakura Finetek, Europe). Serial 14-μm sec-
tions were cut on a microtome cryostat, and thaw–
mounted onto poly-D –lysine (Sigma Aldrich Company
Ltd, Gillingham, UK) coated glass microscope slides. Sec-
tions were collected as 20 sets so that each section was
280 μm from the section adjacent in the same set. Sections
were left to air dry for 1 hour at room temperature, prior
to storage at −80°C until required for processing.
Immunofluorescence
Two sets of slides from each specimen were processed
for indirect immunofluorescence, and dual labelled with
primary affinity-purified antisera to the general neuronal
marker protein gene product 9.5 (PGP9.5) and either so-
dium channel subtype Nav1.8 or Nav1.9 [11,52]. Prior to
staining, the slides were removed from storage and left
to air dry for 1 hour at room temperature. After washing
in phosphate-buffered saline (PBS) (2 × 10 minutes), the
sections were incubated in PBS containing 0.5% Triton
X-100 (PBST) and 20% normal donkey serum (NDS) for
1 hour at room temperature in a moisture chamber,
to reduce non-specific background staining and in-
crease the permeability of cell membranes to the anti-
bodies. The sections were incubated with primary
antibodies raised in rabbit to either sodium channel
Nav1.8 (1:200) or Nav1.9 (1:2000), diluted in PBST
and 5% NDS for 24 hours at 4°C. They were then
washed in PBS (2 × 10 minutes) and incubated for
90 minutes at room temperature with secondary anti-
body raised in donkey against rabbit IgG, conjugated
to indocarbocyanine (Cy3, Jackson ImmunoResearch
Laboratories Inc, USA, 1:500), diluted in PBST con-
taining 1.5% NDS. The tissue was further washed in
PBS (2 × 10 minutes), and then incubated with a
monoclonal primary antibody raised in mouse against
human PGP9.5 overnight at 4°C (UltraClone, 1:1000;
diluent: PBST 5% NDS). The following day the sec-
tions were washed in PBS (2 × 10 minutes) and incu-
bated with a fluorescent secondary antibody, raised indonkey against mouse IgG, conjugated to fluorescein iso-
thiocyanate (FITC; Jackson, 1:50, diluted in PBST contain-
ing 1.5% NDS) for 90 minutes at room temperature. The
sections were washed one final time in PBS (2 × 10 mi-
nutes), mounted in fluorescence-free Vectashield medium
(Vector Laboratories, UK) and coverslipped.
Immunohistochemical controls for PGP9.5, Nav1.8
and Nav1.9 were performed by incubating the tissue sec-
tions with the secondary antibody alone.
Examination and analysis of tissue
Images of sections were acquired with a Zeiss Axioplan
2 Imaging fluorescence microscope, fitted with a HBO
50 mercury lamp, ×10 eyepiece and excitation/emission
filter sets for FITC and Cy3 detection. Image acquisition
and processing was performed using Image-Pro Plus
(v5.1, Media Cybernetics, USA). Analysis was performed
blinded to the specimen group.
A section from approximately the middle of each spe-
cimen was selected for analysis. In order to determine
the proportion of nerve tissue that contained the specific
sodium channel, the percentage area of PGP9.5 labelled
tissue, which was also labelled for the specific sodium
channel, was quantified. For each specimen, the section
that contained the most PGP9.5 labelled tissue was se-
lected for analysis. Preliminary assessments revealed that
analysis of 150,000 μm2 of PGP9.5 labelled tissue pro-
vided an accurate representation of the whole section.
Sampling was undertaken across the full width of the
neuroma, starting from the central cut end of the nerve,
and extending along the nerve for 3 fields of view (×20
objective), or until at least 150,000 μm2 of PGP9.5, had
been analysed.
Initially each field of interest was viewed with the
FITC filter and the area of PGP9.5 labelling measured.
The same field was then viewed with the Cy3 filter in
place and the area of each sodium channel subtype
staining measured. The total area of PGP9.5 and sodium
channel staining within the area analysed was measured
and the total percentage area of PGP9.5 labelled tissue,
which was also positively stained for the sodium channel
calculated.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
(Version 5.0d, GraphPad Software, Inc. La Jolla, CA,
USA). Unpaired sample t-tests were employed to com-
pare the levels of expression of Nav1.8 and Nav1.9 in
non-symptomatic neuroma specimens with symptomatic
neuromas, for differences between neuromas from male
and female patients, and between neuromas from females
with and without symptoms. Differences were considered
statistically significant if p < 0.05. Pearson’s correlation co-
efficients were used to establish any correlations between
Bird et al. Molecular Pain 2013, 9:52 Page 10 of 11
http://www.molecularpain.com/content/9/1/52the expression of Nav1.8 and Nav1.9 and the VAS scores
for pain, tingling, or discomfort; the age of the patient; or
the time between the initial nerve injury and repair.
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